---
format:
  revealjs:
    spotlight: true
    touch: true
    controls: true
    pointer: true
    center-title-slide: false
    transition: fade
    transition-speed: fast
    scrollable: true
    slide-number: true
    incremental: false
    multiplex: false
    chalkboard: true
    theme: [default, custom.scss]
    filters:
     - highlight-text
bibliography: references.bib
lightbox: true
csl: diagnostic-microbiology-and-infectious-disease.csl
---

## Lecture 5: Cephalosporins and carbapenems {background-video="login-lores.mp4" background-video-loop="true" background-opacity="0.3"}

<br> <br> <br> <br>

**Russell E. Lewis** <br> Associate Professor of Infectious Diseases <br> Department of Molecular Medicine <br> University of Padua

<br> {{< fa solid envelope size=1x >}} russelledward.lewis\@unipd.it <br> {{< fa brands github size=1x >}} [https://github.com/Russlewisbo](https://github.com/Russlewisbo/ESCMID_2022_talk)

![](images/University_of_Padua_seal.svg){width="100"}

## Agenda

## Discovery of cephalosporins {.smaller}

<br>

::::: columns
::: {.column width="40%"}
![](images/Bronzu.png){width="800"}
:::

::: {.column width="60%"}
<br>

-   Bronzu performed epidemiological studies of typhoid infection in Cagliari, noted *Salmonella typhi* was not cultured once sewer water was discharged into the sea
-   Isolated the mold *Cephalosporium* (now known as *Acremonium*) in 1948 from seawater
-   Noticed that these cultures produced substances (he named mycetin) that were effective against *Salmonella typhi*, the cause of typhoid fever, which had beta-lactamase.
-   After he failed to find support from Italian government, he sent the fungus to Howard Florey at Oxford
-   1962: Isolation of cephalosporin C
:::
:::::

## Mechanism of action of cephalosporins: <br> Similar to β-lactams

<br>

::::: columns
::: {.column width="50%"}
![Inhibition of transpeptidase (PBP)](https://i.makeagif.com/media/4-07-2017/l7_PRO.gif)
:::

::: {.column width="50%"}
![Lysis of growing bacterial cells](https://i.makeagif.com/media/10-05-2017/e3c7kf.gif)
:::
:::::

<br>

## First generation cephalosporins; <br> derivatives of 7-ACA {.smaller}

![](images/1gen.png){fig-align="center" width="400"}

::: aside
-   Gram positive activity: Cover Methicillin-sensitive *S. aureus* (MSSA) and streptococci:
-   Used for uncomplicated skin and soft-tissue infections (SSI)
-   Surgical prophylaxis: cefazolin
-   Some gram-negative coverage in urine: Non-ESBL producing *P. mirabilis, E. coli, and K. pneumoniae*
:::

## Pharmacokinetics: 1st generation cephalosporins {.smaller}

<br> <br>

+-------------------+-------------------------------------------------------------------+
| **Absorption**    | Cefadroxil (90%); cephalexin (90%); cefazolin (IV only)           |
+-------------------+-------------------------------------------------------------------+
| **Distribution**  | -   0.19-0.35 L/kg                                                |
|                   |                                                                   |
|                   | -   Protein binding: 20% cefadroxil, cephalexin; 73-87% cefazolin |
|                   |                                                                   |
|                   | -   25% bile:serum; cefazolin:29-300%                             |
|                   |                                                                   |
|                   | -   5-10% CSF:blood (possibly for cefazolin with higher doses)    |
+-------------------+-------------------------------------------------------------------+
| **Metabolism**    | -   No metabolism                                                 |
|                   |                                                                   |
|                   | -   t½: Cefazolin (2 hrs); cefadroxil (1.5 hrs); cephalexin (1hr) |
+-------------------+-------------------------------------------------------------------+
| **Elimination**   | Renal 100%, impaired by probenicid                                |
+-------------------+-------------------------------------------------------------------+
| **PK:PD target**  | ≥ 40-50% *f*Time~\>MIC~                                           |
+-------------------+-------------------------------------------------------------------+
| **Typical doses** | Cefazolin: 1-2 gram IV every 8 hours                              |
|                   |                                                                   |
|                   | Cefadroxil: 500-1000 mg BID                                       |
|                   |                                                                   |
|                   | Cephalexin 250-1000 mg QID                                        |
+-------------------+-------------------------------------------------------------------+

## Avoid cefazolin for CNS infections?

<br>

::::: columns
::: {.column width="50%"}
![](images/myth1.png)
:::

::: {.column width="50%"}
![](images/myth2.png)
:::
:::::

::: aside
[@mccreary.etal_2023b]
:::

## Why this myth has been busted?

<br>

-   **Earlier recommendations based on breakthrough reports with cephalothin and single point samples suggesting low CSF concentrations**
-   **More recent data have documented attainment of therapeutic exposures with higher dose regimens:**
    -   A recent narrative review on the treatment of cefazolin for CNS infections (including 11 reports describing cefazolin treatment of spinal epidural abscesses in a total of 104 patients) recommends [2 g IV every 6 hours or a continuous infusion of 8–10 g daily]{bg-color="#ffe536"} instead of the traditional 1–2 g IV every 8 hours dosing scheme to optimize pharmacokinetic/pharmacodynamic properties

::: aside
[@antosz.etal_2023a]
:::

## Another cefazolin myth busted? <br> penicillin cross-allergy {.smaller}

<br>

::::: columns
::: {.column width="50%"}
![](images/myth3.png){width="500"}
:::

::: {.column width="50%"}
![](images/myth4.png){width="600"}
:::
:::::

::: aside
[@mccreary.etal_2023b]
:::

## Second generation cephalosporins {.smaller}

![](images/2ndgen.png){fig-align="center" width="600"}

## Spectrum of activity {.smaller}

<br>

-   **Enhanced Gram-negative coverage:** Effective against a variety of Gram-negative bacilli, including Haemophilus influenzae, Enterobacter aerogenes, Neisseria species, and some Escherichia coli and Klebsiella species.

-   **Gram-positive activity:** Retain good activity against many Gram-positive cocci, such as Streptococcus pneumoniae and Streptococcus pyogenes, but generally less active than first-generation cephalosporins against Staphylococcus aureus.

-   **Anaerobic bacteria:** Some second-generation cephalosporins, like cefoxitin and cefotetan, have activity against anaerobic bacteria, including Bacteroides fragilis, which makes them useful for abdominal infections.

-   **Limited against beta-lactamase producers:** While they have improved resistance to beta-lactamases compared to first-generation cephalosporins, many second-generation cephalosporins are still susceptible to beta-lactamase enzymes produced by certain bacteria, limiting their effectiveness against these resistant strains.

## Pharmacokinetics of representative 2nd generation cephalosporins {.smaller}

<br> <br>

+-------------------+--------------------------------------------------------------------------+
| **Absorption**    | Cefuroxime (52%), cefprozil (95%), cefaclor (93%)                        |
+-------------------+--------------------------------------------------------------------------+
| **Distribution**  | -   0.15-0.35 L/kg                                                       |
|                   |                                                                          |
|                   | -   Protein binding: 36-50%                                              |
|                   |                                                                          |
|                   | -   25% bile:serum; cefazolin:29-300%                                    |
|                   |                                                                          |
|                   | -   5-10% CSF:blood (possibly for cefazolin with higher doses)           |
+-------------------+--------------------------------------------------------------------------+
| **Metabolism**    | -   No metabolism                                                        |
|                   |                                                                          |
|                   | -   t½: cefuroxime (1.5hrs); cefadroxil (1.5 hrs); cefotetan( 3-4 hr) \| |
+-------------------+--------------------------------------------------------------------------+
| **Elimination**   | Renal 100%                                                               |
+-------------------+--------------------------------------------------------------------------+
| **PK:PD target**  | ≥ 40-50% *f*Time~\>MIC~                                                  |
+-------------------+--------------------------------------------------------------------------+
| **Typical doses** | cefaclor: 250-500 mg TID                                                 |
|                   |                                                                          |
|                   | cefuroxime: 250-500 BID                                                  |
|                   |                                                                          |
|                   | cefotetan: 1-2 gram IV q12h                                              |
+-------------------+--------------------------------------------------------------------------+

::: aside
Source: Sanford Guide
:::

## 2nd generation cephalosporins: <br> What is their role?

<br>

-   Cefotetan- GI surgical prophylaxis (resistance is increasing in *B. fragilis*)

-   Upper respiratory tract infections, CAP, gonorrhea,...

    -   but these are "in between" antibiotics and often passed over for better options

## 3rd generation cephalosporins {.smaller}

<br>

![](images/3rdgen.png){fig-align="center" width="400"}

## 3rd generation cephalosporins: spectrum {.smaller}

### Gram-Positive Coverage

-   **Reduced compared to 1st/2nd generation** cephalosporins

-   Moderate activity against **Streptococcus pneumoniae** and other streptococci

-   **Poor activity** against methicillin-resistant Staphylococcus aureus (MRSA)

-   Limited activity against **Enterococcus species**

-   Ceftriaxone maintains reasonable activity against penicillin-susceptible S. pneumoniae

### Gram-Negative Coverage (Primary role)

-   **Excellent activity** against Enterobacteriaceae:

    -   *E. coli*

    -   *Klebsiella species*

    -   *Proteus mirabilis*

    -   *Citrobacter species*

    -   *Serratia marcescens*

-   Good activity against **Haemophilus influenzae** (including β-lactamase producers)

-   Coverage of ***Neisseria gonorrhoeae*** and ***N. meningitidis***

-   **Ceftazidime** uniquely covers ***Pseudomonas aeruginosa***

-   Generally active against ***Moraxella catarrhalis***

## Notable Gaps: <br> 3rd generation cephalosporins {.smaller}

### No activity against:

-   MRSA or methicillin-resistant coagulase-negative staphylococci

-   Enterococcus faecalis/faecium

-   Listeria monocytogenes

-   Atypical pathogens (Mycoplasma, Chlamydia, Legionella)

-   Most anaerobes (except some activity from ceftriaxone/cefotaxime)

-   Extended-spectrum β-lactamase (ESBL) producing organisms

-   AmpC β-lactamase producers

### Key Clinical Agents

-   **Ceftriaxone/Cefotaxime**: Broader spectrum, CNS penetration

-   **Ceftazidime**: Anti-pseudomonal activity

-   **Cefixime**: Oral option with good gram-negative coverage (non-ESBL)

-   **Ceftibuten/Cefdinir**: Other oral options with varying spectra

## Pharmacokinetics: <br>3rd generation cephalosporins {.smaller}

+-------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------+
| **Absorption**    | Cefpodoxime (56%); Cefexime (50%); Cefoperazone (IV); Ceftazidime (IV); Cefotaxime (IV); Ceftriaxone (IV, IM)                                                                               |        |
+-------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------+
| **Distribution**  | -   0.15-0.93 L/kg                                                                                                                                                                          |        |
|                   |                                                                                                                                                                                             |        |
|                   | -   Protein binding: \<10% ceftazidime; 30-70% cefotaxime, cefpodoxime, cefixime; \> 85-90% cefoperazone, ceftriaxone                                                                       |        |
|                   |                                                                                                                                                                                             |        |
|                   | -   CSF/Blood \> 10%: cefotaxime, ceftazidime; ceftriaxone,                                                                                                                                 |        |
+-------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------+
| **Metabolism**    | -   No metabolism                                                                                                                                                                           |        |
|                   |                                                                                                                                                                                             |        |
|                   | -   t½: cefotaxime, ceftazidime, cefoperazone; 1.5-2 hr; cefpodoxime 2.5 hr; cefixime 3hr; ceftriaxone 8 hr;                                                                                |        |
+-------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------+
| **Elimination**   | All renal except: ceftriaxone and cefoperazone undergo primarily biliary elimination                                                                                                        |        |
+-------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------+
| **PK:PD target**  | ≥ 40-50% *f*Time~\>MIC~                                                                                                                                                                     |        |
+-------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------+
| **Typical doses** | Cefotaxime 2 grams IV q8h; cefpodoxime 200-400 mg BID; ceftazidime 1-2 gram IV q8h or 15 mg/kg LD then 6 G IV over 24h; ceftriaxone 1-2 grams IV 24h (q12h meningitis); cefixime 400 mg BID |        |
+-------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------+

## 3rd Generation Cephalosporins: <br> Role in treatment

<br>

-   Extended gram-negative bacteria coverage, often used to treat gram-negative infections resistant to the first- and second-generation or other β-lactam antimicrobials
-   Ceftriaxone and cefotaxime penetrate the blood-brain barrier and cover bacteria in the cerebral spinal fluid
    -   Ceftriaxone can be prescribed to treat meningitis caused by *Haemopohilus influenzae*, *Neisseria meningitidis*, or *Streptococcus pneumoniae*
    -   Ceftriaxone is also used to treat gonorrhea and disseminated Lyme disease
    -   Ceftazidime has *Pseudomonas aeruginosa* coverage

## Key issues with ceftriaxone dosing {.small}

<br>

-   Often avoided in neonates, because of displacement of bilirubin (cefotaxime used instead)
-   2 gram q24h dose has largely replaced 1 gram dose for most indications (similar safety, improved PK/PD target in obese/ critically ill)
    -   Risk for low exposure: low albumin, augmented renal clearance, sepsis
    -   High protein binding a key component that slows ceftriaxone clearance
-   Meningitis dose: 2 gram IV q12h

## Higher failure rates of 2nd and <br> 3rd generation cephalosporins for MSSA? {.small}

-   MSSA MIC breakpoints historically have been too high (MIC ≤ 8) vs. gram negatives (MIC ≤ 1, set to address ESBL test problems)
    -   Oxacillin and cefoxitin susceptibility are probably not a good predictor of ceftriaxone susceptibility among MSSA
-   In vitro, killing by ceftriaxone (esp. in presence of albumin) is much slower versus anti-staphylococcal PCNs
-   Yet, observational clinical studies provide conflicting evidence whether ceftriaxone is inferior
-   In clinical PK/PD analysis, ceftriaxone 2 grams daily had a clinical failure rate of 55%, which was almost the same as vancomycin 1 gram Q12
    -   Ceftriaxone 2 gram q12 needed to give the best chance of covering MSSA
    -   OPAT convenience: cefazolin 2 gram q12h or daptomycin 6-8 mg/kg once daily

::: aside
[@paul.etal_2011; @zelenitsky.etal_2018]
:::

## Ceftriaxone for enterococcal endocarditis? {.smaller}

-   Aminoglycoside sparing regimens for *E. faecalis* endocarditis: Ceftriaxone + ampicillin
    -   *E. faecalis* has 5 PBPs
    -   At high doses, ampicillin will bind PBP 1,4,5 and ceftriaxone will bind PBPs 2,3
    -   Binding all 5 PBP creates potent synergy
    -   Need to use 2 gram IV q12h of ceftriaxone

![](images/Screenshot%202024-10-29%20at%2017.17.34.png){width="800"}

::: aside
[@fernandez-hidalgo.etal_2013]
:::

## β-lactamases: Ambler classification {.smaller}

![](images/Ambler.png){fig-align="center" width="800"}

## ESBL resistance

<iframe width="1200" height="900" src="https://resistancemap.onehealthtrust.org/AntibioticResistance.php" title="Resistance Map">

</iframe>

## Ceftazidime-avibactam

![](images/carbapenemase_spectrum.png){fig-align="center"}

::: aside
[@tamma.hsu_2019] <br> Green, susceptibility anticipated to be \>80%; yellow, susceptibility anticipated to be 30% to 80%; red, intrinsic resistance or susceptibility anticipated to be \<30%.
:::

## 4th, 5th and 6th generation cephalosporins {fig-align="center"}

<br>

![](images/5th%20and6th.png){fig-align="center" width="600"}

## Spectrum of activity

<br>

### 4th Generation (Cefepime) {.smaller}

**Key feature: Enhanced stability against AmpC β-lactamases**

**Gram-Positive Coverage:**

-   Better than 3rd generation, similar to 2nd generation

-   Good activity against **Streptococcus pneumoniae** and viridans streptococci

-   Moderate activity against **methicillin-susceptible S. aureus** (MSSA)

-   No MRSA or Enterococcus coverage

**Gram-Negative Coverage:**

-   Excellent **Enterobacteriaceae** coverage, including AmpC producers:

    -   Enterobacter species

    -   Citrobacter freundii

    -   Serratia marcescens

    -   Providencia species

    -   Morganella morganii

-   **Pseudomonas aeruginosa** coverage comparable to ceftazidime

-   Maintains activity against organisms resistant to 3rd generation cephalosporins

## Cefiderocol

<br>

![](images/cefiderocol.png){fig-align="center" width="600"}

::: aside
Image: <https://www.fetroja.com/overcoming-carbapenem-resistance>
:::

## Cefiderocol ( ): <br> How does it overcome resistance?

<br>

![](images/cefiderocol2.png){fig-align="center" width="600"}

::: aside
Image: <https://www.fetroja.com/overcoming-carbapenem-resistance>
:::

## Pharmacokinetics of 4 to 6th generation cephalosporins {style=".smaller"}

<br>

+-------------------+--------------------------------------------------------------------------------------------------+----------+
| **Absorption**    | All intravenous formulations                                                                     |          |
+-------------------+--------------------------------------------------------------------------------------------------+----------+
| **Distribution**  | -   0.19-0.3 L/kg                                                                                |          |
|                   | -   protein binding 20-40%                                                                       |          |
|                   | -   CSF penetration 20-40% (therapeutic)                                                         |          |
+-------------------+--------------------------------------------------------------------------------------------------+----------+
| **Metabolism**    | -   No metabolism, renally eliminated                                                            |          |
|                   |                                                                                                  |          |
|                   | -   t½: cefepime (2hr); ceftaroline (2-3 hr); cefiderocol (3hr); ceftolozane-tazobactam (3.1 hr) |          |
+-------------------+--------------------------------------------------------------------------------------------------+----------+
| **Elimination**   | All renal                                                                                        |          |
+-------------------+--------------------------------------------------------------------------------------------------+----------+
| **PK:PD target**  | ≥ 40-50% *f*Time~\>MIC~                                                                          |          |
+-------------------+--------------------------------------------------------------------------------------------------+----------+
| **Typical doses** | -   Cefepime 1-2 gram IV q8h or 15 mg/kg IV push, then 6 grams IV over 24 hours;                 |          |
|                   |                                                                                                  |          |
|                   | -   Ceftaroline 600 mg IV q8-12h;                                                                |          |
|                   |                                                                                                  |          |
|                   | -   Cefiderocol 2 grams IV q8h over 3 hours;                                                     |          |
|                   |                                                                                                  |          |
|                   | -   Ceftolozane-tazobactam 3 grams over 3 hours q8 hours                                         |          |
+-------------------+--------------------------------------------------------------------------------------------------+----------+

## 4 and 5th generation cephalosporin resistance in Gram negatives

<br>

**In addition to porin channel alterations, efflux pumps...**

-   **Cefepime:** MBLs and serine beta-lactamases (ESBLs); PBP3 insertions; OXA-48 enzymes

-   **Ceftazidime-avibactam:** β-Lactamase mutations and overexpression (e.g.,KPC-3 D179Y, T243M, and V240G); penicillin binding protein (PBP) alterations, efflux pump overexpression, porin mutations and deficiencies, AmpC β-Lactamase alterations

-   **Cefiderocol:** Siderophone uptake/receptor mutations (pirA and cirA), PBP3 Mutations, NDM, KPC and AMPC mutations

-   **Ceftolozane-tazobactam:** MBLs, ESBLs (CTX-M-15; CMY-10); OXA -type β-Lactamases (OXA-10, OXA-14), OXA-794, OXA 795), PBP alterations

## PBP3 insertions

![](images/pbp.png){fig-align="center" width="600"}

[@sethuvel2023]

## Carbapenems

![](images/carbapenems.png){fig-align="center" width="600"}

## Spectrum of activity {.smaller}

• **Broad gram-positive coverage**: Active against most gram-positive bacteria including methicillin-sensitive *Staphylococcus aureus* (MSSA), Streptococcus species (including penicillin-resistant *S. pneumoniae*), and *Enterococcus faecalis.* However, they lack activity against methicillin-resistant Staphylococcus aureus (MRSA) and Enterococcus faecium.

• **Excellent gram-negative coverage**: Highly effective against Enterobacterales (*E. coli, Klebsiella, Proteus, Serratia, Citrobacter, Enterobacte*r) including many ESBL and AmpC-producing strains, making them crucial for treating multidrug-resistant gram-negative infections.

• ***Pseudomonas aeruginosa*** **activity**: Most carbapenems (except ertapenem) have anti-pseudomonal activity, though resistance is increasingly common. Doripenem and meropenem generally have better anti-pseudomonal activity than imipenem.

• **Anaerobic coverage**: Excellent activity against both gram-positive and gram-negative anaerobes including *Bacteroides fragilis* group, Clostridium species (except *C. difficile*), *Fusobacterium*, and *Peptostreptococcus*, making them suitable for polymicrobial infections.

• **Atypical pathogen gaps**: Limited or no activity against atypical pathogens including *Mycoplasma, Chlamydia, Legionell*a, and mycobacteria, requiring alternative agents for these infections.

• **Intrinsic resistance patterns**: Naturally inactive against *Stenotrophomonas maltophilia, Burkholderia cepacia* complex, and most *Acinetobacter* species (though imipenem may retain some *Acinetobacter* activity).

• **Unique spectrum considerations**: Ertapenem lacks anti-pseudomonal and anti-*Acinetobacter* activity but has a longer half-life allowing once-daily dosing, while newer combinations like meropenem-vaborbactam and imipenem-relebactam restore activity against some KPC-producing Enterobacterales.

## What is not covered?

## Gram-Positive Gaps

-   **MRSA (Methicillin-resistant Staphylococcus aureus)** - One of the most important gaps; requires vancomycin, daptomycin, linezolid, or other anti-MRSA agents

-   **Enterococcus faecium** - Intrinsically resistant; particularly problematic as VRE (vancomycin-resistant enterococci)

-   **Coagulase-negative staphylococci (methicillin-resistant)** - Common cause of device-related and catheter infections

## Gram-Negative Gaps {.smaller}

-   **Stenotrophomonas maltophilia** - Intrinsically resistant due to L1 metallo-β-lactamase; requires trimethoprim-sulfamethoxazole or alternatives

-   **Burkholderia cepacia complex** - Intrinsically resistant; important in cystic fibrosis patients

-   **Carbapenem-resistant Enterobacterales (CRE)** - Including KPC, NDM, OXA-48 producers; increasingly common worldwide

-   **Carbapenem-resistant Acinetobacter baumannii** - Major nosocomial pathogen with high mortality

-   **Serratia spp. (imipenem)**

-   **Elizabethkingia** (formerly Chryseobacterium) **meningosepticum** bapenem-Resistant Organisms **"Stay Alert Elizabeth"**

-   **S** - ***Stenotrophomonas maltophilia*** - L1 and L2 β-lactamases; requires TMP-SMX

-   **A** - ***Aeromonas species*** - Some strains produce metallo-β-lactamases (though variable resistance)

-   **E** - ***Elizabethkingia meningosepticum*** - Multiple β-lactamases including metallo-β-lactamases

## Ertapenem- APE spectrum hole

## Pharmacokinetics of Carbapenem Antibiotics {.smaller}

+-------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Parameter         | Characteristics                                                                                                                                                                                                                                                                               |
+===================+===============================================================================================================================================================================================================================================================================================+
| **Absorption**    | All intravenous formulations (ertapenem also IM)                                                                                                                                                                                                                                              |
+-------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| **Distribution**  | • Vd: 0.15-0.35 L/kg<br>• Protein binding varies widely:<br>  - Imipenem: 20%<br>  - Meropenem: 2%<br>  - Doripenem: 8%<br>  - Ertapenem: 85-95%<br>• CSF penetration: 10-30% (inflamed meninges)                                                                                             |
+-------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| **Metabolism**    | • Minimal hepatic metabolism<br>• Imipenem requires cilastatin to prevent renal metabolism by DHP-I<br>• t½:<br>  - Imipenem: 1 hr<br>  - Meropenem: 1 hr<br>  - Doripenem: 1 hr<br>  - Ertapenem: 4 hr                                                                                       |
+-------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| **Elimination**   | • Primarily renal (70-95%)<br>• Dose adjustment required for CrCl \<50 mL/min<br>• Removed by hemodialysis (except ertapenem)                                                                                                                                                                 |
+-------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| **PK/PD Target**  | ≥40% fT\>MIC (optimal bactericidal: ≥70% fT\>MIC)                                                                                                                                                                                                                                             |
+-------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| **Typical Doses** | • **Imipenem-cilastatin**: 500mg-1g IV q6-8h<br>• **Meropenem**: 1-2g IV q8h (3g q8h for meningitis)<br>• **Doripenem**: 500mg IV q8h over 1-4 hours<br>• **Ertapenem**: 1g IV/IM q24h<br>• **Meropenem-vaborbactam**: 4g q8h over 3 hours<br>• **Imipenem-cilastatin-relebactam**: 1.25g q6h |
+-------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+

**Note**: Extended infusions (3-4 hours) optimize PK/PD target achievement, especially for resistant organisms with elevated MICs.

## Carbapenem side effects

-   Seizures: Impinem \> meropenem, ertapenem

-   Phlebitis 4%

-   Neutropenia

-   Eosinophilia

-    DRESS

-   Diarrhoea 6%

-   Deranged LFTs 6%

## References